neue freunde finden als erwachsener
If you wish to go to ZacksTrade, click OK. The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. NASDAQ data is at least 15 minutes delayed. Alexion Pharmaceuticals's EPS without NRI … Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank, Industry: Medical - Biomedical and Genetics. Alexion Pharmaceuticals, Inc. (ALXN) Quote Overview, Alexion Pharmaceuticals, Inc. (ALXN) Fundamental Charts PE Ratio (TTM), Immunovant (IMVT) Gains on a Potential Buyout by Roivant. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. ... especially in companies that are growing faster than the general market and whose price earnings multiples seemed quite high when compared to other stocks. And the median was 69.85. It’s Quick Ratio in the last reported quarter now stands at 4.30. PE Ratio … Financial ratios and metrics for Alexion Pharmaceuticals stock (ALXN). Historical price to book ratio values for Alexion Pharmaceuticals (ALXN) over the last 10 years. The monthly returns are then compounded to arrive at the annual return. Alexion Pharmaceuticals (NAS:ALXN) Forward PE Ratio Explanation. Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus, Nasdaq ETF's Worst Day Since October: Stocks That Survived, Zacks.com featured highlights include: Sanmina Corp, Canadian Solar, Celestica and Alexion Pharmaceuticals, Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market, Alexion Pharmaceuticals Inc. stock falls Thursday, underperforms market, Alexion Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, Alexion Pharmaceuticals Inc. stock outperforms market on strong trading day. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. The historical average of roughly 15 shows a poor value for ALXN stock as investors are paying higher share prices relative to the company's earnings. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. This includes personalizing content and advertising. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. The Stock has managed to achieve an average true range (ATR) of 2.46. * indicates the important links in the menu. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value. Alexion Pharmaceuticals PE Ratio 2006-2020 | ALXN. Alexion Pharmaceuticals PE ratio as of March 12, 2021 is 12.98. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole. During the past 13 years, Alexion Pharmaceuticals's highest PE Ratio without NRI was 393.12. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. We use cookies to understand how you use our site and to improve your experience. Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion Pharmaceuticals has a 12 month low of $72.67 and a 12 month high of $162.60. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Shareholders might … The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Alexion Pharmaceuticals, Inc. (ALXN) receives a strong valuation ranking of 87 from InvestorsObserver's data analysis. Visit www.zacksdata.com to get our data and content for your mobile app or website. On this front, Alexion has a trailing twelve months PE ratio of 12.85, as you can see in the chart below: The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. ALXN's high trailing PE ratio shows that the firm has been trading above its fair market value recently. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Alexion Pharmaceuticals PE ratio as of March 05, 2021 is 12.85. ALXN's current price/earnings ratio is 55.89, which is higher than 80.4% of US stocks with positive earnings. See rankings and related performance below. In depth view into Alexion Pharmaceuticals PE Ratio (Forward) including historical data from 1996, charts, stats and industry comps. Holz previously noted that Alexion has been one of the cheapest stocks among mid- to large-cap biotechs based on its price-earnings ratio. Alongside those numbers, its PE Ratio stands at $26.92, and its Beta score is 1.36. Zacks Investment Research is releasing its prediction for ALXN based on the 1-3 month trading system that nearly triples the S&P 500. ZacksTrade and Zacks.com are separate companies. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Of note is the ratio of Alexion Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 15.5% of US stocks have a lower such ratio. This makes Alexion a solid choice for value investors, and some of its other key metrics make this pretty clear too. Alexion Pharmaceuticals develops and commercializes various therapeutic products. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.93% per year. The PEG ratio is a modified PE ratio that … In general, a lower number or multiple is usually considered better than a higher one. Includes annual, quarterly and trailing numbers with full history and charts. Therefore, Alexion Pharmaceuticals's PE Ratio without NRI for today is 58.36. The current price to book ratio for Alexion Pharmaceuticals as of February 19, 2021 is 2.96 . For a detailed definition, formula and example for. Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Please refer to the Stock Price Adjustment Guide for more information on our historical prices. For example, the PEG ratio for Alexion is just 0.95, a level that is lower than the industry average of 1.86. The lowest was 7.57. If you do not, click Cancel. Compare ALXN With Other Stocks If earnings are expected to grow in the future, the Forward PE Ratio will be … Please check your download folder. Alexion Pharmaceuticals's PEG ratio. It is the most commonly used metric for determining a company's value relative to its earnings. The scores are based on the trading styles of Value, Growth, and Momentum. It compares a stock’s price per share to the stock’s earnings per share. NasdaqGS:ALXN PE PEG Gauge July 16th 18. PE vs Market : ALXN is poor value based on its PE Ratio … The P/E ratio is a popular ratio used in relative valuation since earnings power is a key driver of investment value. Delayed quotes by Sungard. About ALXN. Real time prices by BATS. ALXN has a trailing twelve month Price to Earnings ratio of 37.1. For example, the PEG ratio for Alexion is 0.91, a level that is lower than the industry average of 1.46. Please refer to the Stock Price Adjustment Guide for more information on our historical prices. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. Price to Earnings Ratio or P/E is price / earnings. NYSE and AMEX data is at least 20 minutes delayed. Current and historical p/e ratio for Alexion Pharmaceuticals (ALXN) from 2006 to 2020. It's packed with all of the company's key stats and salient decision making information. Learn more about Zacks Equity Research reports. Let’s observe the current performance indicators for Alexion Pharmaceuticals Inc. (ALXN). This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9651. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. Zacks Rank Education -- Learn more about the Zacks Rank Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Zacks Ranks stocks can, and often do, change throughout the month. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ... Alexion … In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report? ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. These returns cover a period from January 1, 1988 through January 4, 2021. Please check your download folder. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. About PE Ratio (TTM) Alexion Pharmaceuticals has a trailing-twelve-months P/E of 12.09X compared to the Medical - Biomedical and Genetics industry's P/E of …Batch Code Prüfen, Farbkreis Pdf Drucken, Verschiedene Berufe Bei Der Polizei, Finanzfluss Campus Kostenlos, Ade Zur Guten Nacht Tonart, Gesundheitsamt Trier Corona-test, Fahrschulen Corona Sachsen Aktuell, Zählen Wenn Nicht Leer,